The U.S. government is investing $231.8 million to ramp up production from an Australian manufacturer of at-home Covid-19 tests that don’t require a prescription, according to an announcement Monday. Read More
Categories
The U.S. government is investing $231.8 million to ramp up production from an Australian manufacturer of at-home Covid-19 tests that don’t require a prescription, according to an announcement Monday. Read More